Tumor markers in ovarian carcinoma

International Journal of Gynecology and Obstetrics

Volumn 97, Issue 3, 2007, Pages 175-181

  Raspollini, M R ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Cyclooxygenase; Ovarian carcinoma; Prognostic factors; Responsiveness to chemotherapy

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PACLITAXEL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GRADING; DRUG EFFICACY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

EID: 34248329884     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2007.02.011     Document Type: Review

References (72)

1. McCluggage W.G., and Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47 3 (2005) 231-247
2. Baker P.M., and Oliva E. Immunohistochemistry as a tool in the different diagnosis of ovarian tumors: an update. Int J Gynecol Path 24 (2005) 39-55
3. Ozol F.R. Ovarian cancer. In: Steele G.D., Phillips T.L., and Chabner B.A. (Eds). Atlas of Clinical Oncology (2003), BC Decker Inc, Hamilton
4. Ozol R.F. Update of the NCCN ovarian cancer practice guidelines. Oncology (Huntingt) 11 (1997) 95-105
5. Copeland L.J., Bookman M., and Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 90 (2003) S1-S7 (suppl)
6. Stuart G.C. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 90 (2003) S8-S15 (suppl)
7. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
8. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., and Angeletti C.A. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 340 (1992) 145-146
9. Gasparini G., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous cell carcinoma. Int J Cancer 55 (1993) 739-744
10. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis{single bond}correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
11. Ogawa S., Kaku T., Kobayashi H., Hirakawa T., Ohishi Y., Kinukawa N., et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176 (2002) 111-118
12. Orre M., Lotfi-Miri M., Mamers P., and Rogers P.A. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. Br J Cancer 77 (1998) 2204-2209
13. Cuatrecasas M., Villanueva A., Matias-Guiu X., and Prat J. K-ras mutation in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
14. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55 (1995) 4575-4580
15. Singer G., Kurman R.J., Chang H.-W., Cho S.K., and Shih I. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160 (2002) 1223-1228
16. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin, I. Science 265 (1994) 1582-1584
17. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other disease. Nature 407 (2000) 249-257
18. Brower V. Tumor angiogenesis-new drugs on the block. Nat Biotechnol 17 (1999) 963-968
19. Taraboletti G., and Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1 (2001) 378-384
20. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V., and Taddei G.L. Prognostic significance of microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14 (2004) 815-823
21. Miller K.D., Sweeney C.J., and Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19 (2001) 1195-1206
22. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev 19 (2000) 67-73
23. Taraboletti G., Micheletti G., Rieppi M., Poli M., Turatto M., Rossi C., et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8 (2002) 1182-1188
24. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
25. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
26. Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., and Smith S.K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77 (1997) 607-614
27. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., et al. Expression of the vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasm: correlation with clinicopathology and patients survival, and analysis of serum VEGF levels. Br J Cancer 76 (1997) 1221-1227
28. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237 (1999) 1-30
29. Shen G.H., Ghazizadeh M., Kawanami O., Shimizu H., Jin E., Araki T., et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2 (2000) 196-203
30. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., et al. COX-2 status in relation to tumor microvessel density (MVD) and VEGF expression: analysis in ovarian carcinoma patients with low and high survival. Oncol Rep 11 (2004) 309-313
31. Peppelenbosch M.P., Tertoolen L.G., Hage W.J., and de Laat S.W. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cells 74 (1993) 565-575
32. Chen C.C., Sun Y.T., Chen J.J., and Chang Y.J. Tumor necrosis factor-alpha induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 59 (2001) 493-500
33. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in APC delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87 (1996) 803-809
34. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta716) knockout mice. Nat Med 7 (2001) 1048-1051
35. Gupta R.A., and Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1 (2001) 11-21
36. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
37. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58 (1998) 362-366
38. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
39. Tsujii M., kawano S., and DuBois R.N. Cyclooxygenase expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94 (1997) 3336-3340
40. Fernandez P.M., Manyak M.J., and Paterno S.R. Effect of the cyclooxygenase-2 selective inhibitor NS398 on the secretion of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1 TIMP-2) from human prostate tumor cells. Proc Am Assoc Cancer Res 41 (2000) 131-132
41. Kakiuchi Y., Tsujii S., and Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res 62 (2002) 1567-1572
42. Ali-Fehmi R., Morris R.T., Bandyopadhyay S., Che M., Schimp V., Malone Jr. J.M., et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192 (2005) 819-825
43. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 92 (2004) 806-812
44. Zhang T., Guan M., Jin H.Y., and Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol 97 (2005) 501-507
45. Bosch I., and Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288 (1996) 37-54
46. Nooter K., and Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63 (1991) 663-669
47. Kuwano M., Toh S., Uchiumi T., Takano H., Kohno K., and Wada M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Res 14 (1999) 123-131
48. Materna V., Pleger J., Hoffmann U., and Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94 (2004) 152-160
49. Penson R.T., Oliva E., Skates S.J., Glyptis T., Fuller Jr. A.F., Goodman A., et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93 (2004) 98-106
50. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88 (1996) 1442-1455
51. Wei S.H., Brown R., and Huang T.H. Aberrant DNA methylation in ovarian cancer: is a epigenetic predisposition to drug response?. Ann N Y Acad Sci 983 (2003) 243-250
52. Strathdee G., MacKean M., Illand M., and Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH 1 expression and drug resistance in ovarian cancer. Oncogene 18 (1999) 2335-2341
53. Arao S., Suwa H., Mandai M., Tashiro H., Miyazaki K., Okamura H., et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54 (1994) 1355-1359
54. Sweeten K.M., Gershenson D.M., Burke T.W., Morris M., Levenback C., and Silva E.G. Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC). Gynecol Oncol 59 (1995) 211-215
55. Itamochi H., Kigawa J., Sugiyama T., Kikuki M., and Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100 (2002) 281-287
56. Raspollini M.R., Amunni G., Villanucci A., Boddi V., and Taddei G.L. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression are associated with chemotherapy resistance and poor prognosis: analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15 (2005) 255-260
57. Oggionni M., Pilotti S., Suardi S., Ditto A., Luoni C., Mariani L., et al. p53 gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. Oncology 69 (2005) 154-158
58. Richardson A., and Kaye S.B. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 8 (2005) 311-321
59. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
60. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
61. Raspollini M.R., Castiglione F., Rossi Degl'Innocenti D., Amunni G., Villanucci A., Garbini F., et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 16 (2005) 590-596
62. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164 (2000) 361-370
63. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
64. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
65. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn Jr. P.A., and Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59 (1999) 6178-6184
66. Munkarah A.R., Genhai Z., Morris R., Baker V.V., Deppe G., Diamond M.P., et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 88 3 (2003) 429-433
67. Crijns A.P., Duiker E.W., de Jong S., Willemse P.H., van der Zee A.G., and de Vries E.G. Molecular prognostic markers in ovarian cancer. Int J Gynecol Cancer 16 suppl 1 (2005) S152-S165
68. Sallinen S.L., Sallinen P.K., Haapasalo H.K., Helin H.J., Helen P.T., Schraml P., et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60 23 (2000) 6617-6622
69. Nocito A., Bubendorf L., Tinner E.M., Suess K., Wagner U., Forster T., et al. Microarray of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194 3 (2001) 349-357
70. Fowler J.M., Ramirez N., Cohn D.E., Kelbick N., Pavelka J., Ben-Shachar I., et al. Correlation of endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol 192 4 (2005) 1262-1273
71. Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95 (2003) 105-112
72. Berek J.S. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 4 7 (2004) 1159-1165